October 13, 2023 11:06 AM EDT

Harmony Biosciences' Wakix fails PhIII hypersomnia study; Florida gene therapy startup downsizes

Kyle LaHucik

Senior Reporter

Amber Tong

Plus Phase II data on ABION’s MET tyrosine kinase inhibitor, and 60 Degrees Pharmaceuticals giving up on repurposing its antimalarial drug for Covid-19.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Harmony Biosciences' Wakix fails PhIII hypersomnia study; Florida gene therapy startup downsizes

Kyle LaHucik

Senior Reporter

Amber Tong

Sign up to read this article for free.

GSK plots regulatory filings for PBC itch after positive Phase 3 readout

Chinese drugmaker receives FDA warning letter after management hindered inspection

J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success

NICE has 'done all we can' to negotiate for Enhertu coverage, reaffirms decision not to recommend

Are programs with compounded GLP-1s safe for your population?

Har­mo­ny Bio­sciences' Wak­ix fails PhI­II hy­per­som­nia study; Flori­da gene ther­a­py start­up down­sizes

Senior Reporter

Sign up to read this article for free.

Harmony Biosciences' Wakix fails PhIII hypersomnia study; Florida gene therapy startup downsizes